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Concerns about undue influence of sponsors on research 
have already been heard for decades. Efforts to change 
this situation have had insufficient impact. Here we 
draw attention to an innovative proposal by the Royal 
Netherlands Academy of Sciences on how to prevent 
sponsor-induced bias. 
Is the problem still urgent? Several studies suggest that it 
is. In a recent survey of the 289 most-cited clinical trials 
published between 1994 and 2003, Ioannidis’ group 
analysed the origin of authors (academic or nonacademic) 
and the source of finance of these trials.1 This study was 
done within the context of the International Campaign 
to Revitalise Academic Medicine (ICRAM).2 During the 
period of observation, the proportion of investigations 
financed by pharmaceutical industries increased 
significantly: no less than 65 of the 77 most-cited clinical 
trials were (co-)financed with money from industry.
Obviously the increasing influence of industry is a reason 
for concern, especially when the boundaries of influence 
are unclear. Industrial involvement, particularly in drug 
trials, usually starts with the design of the study, the choice 
of the comparator drugs, and the selection of the clinical 
investigators. Often industry has a major involvement in the 
collection and control of the data, as well as in data analysis. 
Even the (ghost)writing of the article may be done by the 
sponsor. 
It is of quite some concern, as Kjaergard and Als-Nielsen 
have pointed out, that authors of trials with competing 
interests, i.e., those funded by for-profit organisations, 
are significantly more positive towards the results of their 
investigation than those without.3 This observation fits 
in with the results of the systematic review by Lexchin 
et al.,4 which demonstrates that studies sponsored 
by pharmaceutical companies are more likely to have 
outcomes favourable to these sponsors than investigations 
that received other funding. A recent survey of major 
clinical trials in the cardiovascular field showed similar 
results: trials funded by for-profit organisations were more 
likely to report positive findings than those supported 
by not-for-profit organisations.5 Similar bias was seen 
in nutrition studies supported by dairy and beverage 
companies.6 
But there are more reasons for concern: after publication, 
the study results may serve as promotional material and 
be selectively used to inform prescribers and potential 
consumers. In this process the investigators may be used 
as a vehicle.7,8
In addition, industrial influence may sneak into the process 
of development of professional protocols and guidelines. 
A recent, rather scary example is the Surviving Sepsis 
Campaign, a basically marvellous initiative aiming at 
standardising and improving the basic care for patients 
with sepsis. In this campaign, however, one particular 
industry, with a major interest, seems to have gained a 
pivotal position. 
In a recently published perspective in the New England 
Journal of Medicine, this story has been described 
in detail.9 The attempts of industry to influence the 
development and – more seriously – the contents of 
practice guidelines are not new. It has been found that 87% 
of authors of guidelines have ties with industry and these 
are often not revealed.10
Of concern are also the relationships between industry 
and members of institutional review boards (IRB). In a 
recent survey, Campbell et al.11 investigated the financial 
relationships between IRB members and industry and 
found that some 36% of these members had some kind of 
financial relationship with industry. Formal disclosure of 
relationships with industry is not required by 33% of IRB. 
Of the respondents, 15.6% reported that in their experience 
at least once a protocol had been presented in a biased way 
by an IRB member with industrial ties.11
Also in daily practice, there is a strong influence of 
industry. In fact, it is a rather sad finding that 
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representatives of pharmaceutical industries often have 
a greater influence on prescribing habits than prevailing 
hospital protocols and objective appraisals in the literature. 
The persuasion of these pharmaceutical representatives is 
often reached with the help of ‘beads and mirrors’, rather 
than through solid information. These practices still persist 
despite initiatives to regulate the interaction between 
pharmaceutical industry and prescribing physicians. 
The Dutch Ministry of Health has issued a series of 
regulations in this respect, starting in 1999, and initially 
these measures met with quite some effect, but it is our 
impression that the effect has waned in recent years. It is 
interesting to note that industry is not the only party that 
tries to influence outcome and reporting of science. For 
instance, governmental bodies may assign investigations 
and selectively use the outcome of the research and may 
require that the results of the investigations are kept 
secret.12
If we return to the core of the problem, it is clear that the 
influence of industry on clinical research is too strong 
and difficult to disentangle. In 2001, the International 
Committee of Medical Journal Editors (ICMJE) took the 
important initiative to ask for a disclosure of conflicts of 
interests of all authors (and to publish those as part of the 
article that reports the investigation). A further definite 
step forward – aimed at preventing selective reporting – is 
the registration of clinical trials in a public repository at 
their inception.13 See also www.clinicaltrials.gov. In this 
repository, the role of the sponsor is also revealed. 
Still, there is a need for better regulation of the relationship 
between sponsor or client and researcher. In a recent 
advice to the Dutch Minister of Science and Education, 
The Royal Netherlands Academy of Arts and Sciences 
(KNAW) voiced its concern about the independence of the 
investigator, and proposes a code of conduct (figure 1) to 
be signed by the university or other research institute that 
performs the investigation.12 The declaration proposes that 
research institutes that wish to be certified as adherent 
to this code must maintain a list of all the research 
contracts concluded by them. Contracts would be open to 
inspection by the National Council on Research Integrity 
(LOWI) which resides within the Academy ( figure 1, 
Clause 9). The Council could demand a copy of a specific 
contract, and could therefore perform random or directed 
inspections. If the text of a contract were found to violate 
the code, the Council could revoke the certification of 
the research institute. As yet, the Dutch government has 
not declared whether it will implement this code. We 
feel that acceptance and implementation of this code is 
an essential next step to create clarity in the relationship 
between research institutes and sponsors, and in the field 
of medicine it may help to control the unwanted influence 
of pharmaceutical industry. 
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figure 1 Declaration of scientific independence*
1. The structure of the research shall not be geared towards 
producing the desired outcome for the client.
2. The assignment and its objective shall preferably be formu-
lated jointly by the client and the researcher.
3. Remuneration and other tokens of appreciation shall never 
depend on the outcome or interpretation of the research.
4. The results of the scientific research shall be published  
irrespective of whether they are favourable to the client.
5. The scientist shall always be free to publish the findings of 
the research within a specified reasonable period of time. 
In this context two months can be regarded as a reason-
able period, with six months generally the maximum (this 
period being calculated from the moment that the final 
results are submitted to the client). An exception should 
be made where there are issues of intellectual property in 
which case a period of no longer than 12 months would be 
acceptable.
6. The method of publication shall be stipulated in the 
contract. Publication in a scientific journal shall take place 
in consultation with the client, but the researcher shall have 
the final say on the contents, the authors, the form of publi-
cation and where the research will be published.
7. External financiers of research assignments and/or other 
sponsors shall be mentioned by name in publications and 
other forms of disclosure.
8. Relevant interests and/or advisory relations of the 
researcher(s) shall be cited in publications and other forms 
of disclosure.
9. The text of the contract shall be available for inspection in 
confidence by the National Council on Research Integrity 
(LOWI). 
* This declaration forms the heart of the code of conduct proposed 
by the royal Netherlands Academy of sciences.12
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